<DOC>
	<DOCNO>NCT02092896</DOCNO>
	<brief_summary>The purpose study : Part 1 : To investigate 12 week treatment liraglutide affect glycemic control poorly control patient treatment affect gastric empty rate hypoglycemia . Part 2 : To investigate 12 week treatment type 1 diabetic patient liraglutide affect counterregulatory hormone cognitive performance hypoglycemia .</brief_summary>
	<brief_title>Liraglutide add-on Insulin Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Age : 1870 year BMI : 1828 HbA1c ≥ 8 % No residual βcell function ( glucagon test cpeptide &lt; 60 pM ) Caucasian Diagnosed type 1 diabetes 5 40 year age ( inclusive ) . Remission phase must complete Female participant must use adequate contraception Informed consent Overt diabetes complication ; creatinin &gt; 130 µM , proliferative retinopathy , macroalbuminuria . Autonomic neuropathy ( RRvariation &lt; /=10 beats/min ) and/or Orthostatic hypotension ( OH ) . Anemia , Hb concentration ; female &lt; 7.0 mmol/l , male &lt; 8.0 mmol/l Pregnancy lactation Epilepsy Use antiepileptic medication Use beta blocker Previously apoplexy cerebri . Any use benzodiazepine within last month Any use neuroleptic drug within last six month Selfperceived hearing loss Alcohol drug abuse Allergy medication placebo . Treatment medication affect glucose metabolism . Any disorder investigator opinion could interfere safety result trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Mellitus , Type 1</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Cognitive performance</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Insulin</keyword>
	<keyword>Glucagon-Like Peptide 1</keyword>
	<keyword>Hypoglycemic Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Incretins</keyword>
	<keyword>Hormones</keyword>
</DOC>